Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI-1206 Alone and With Rituximab in B-cell Malignancy
NCT02933320Phase 2Completed
- Sponsor
- Cancer Research UK
- Start
- Oct 2016
- Primary completion
- Mar 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of BI-1206 in B cell lymphoma, chronic lymphocytic leukemia (CLL), Waldenström macroglobulinemia (WM) and 1 more (4 arms), sponsored by Cancer Research UK. Primary endpoint: Adverse Events, Serious Adverse Events, Dose Limiting Toxicities. Started Oct 2016; status: completed.
02
Drugs
BI-1206
03
Conditions
B cell lymphomachronic lymphocytic leukemia (CLL)Waldenström macroglobulinemia (WM)mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT02933320.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02933320.